Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy.
PLoS ONE, 2019 Radiological biomarkers have been reported for multiple system atrophy and progressive supranuclear palsy, but serum/plasma biomarkers for each disorder have not been established.
Akio Mori +10 more
doaj +1 more source
A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy.
PLoS ONE, 2013 ObjectiveWe studied the annual change in measures of motor, oculomotor and cognitive function in progressive supranuclear palsy. This had twin objectives, to assess the potential for clinical parameters to monitor disease progression in clinical trials ...
Boyd C P Ghosh +2 more
doaj +1 more source
18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. [PDF]
, 2016 The ability to assess the distribution and extent of tau pathology in Alzheimer's disease and progressive supranuclear palsy in vivo would help to develop biomarkers for these tauopathies and clinical trials of disease-modifying therapies.
Aigbirhio, Franklin I +17 more
core +1 more source
Comparison of gait in progressive supranuclear palsy, Parkinson’s disease and healthy older adults
BMC Neurology, 2012 Background Progressive supranuclear palsy and Parkinson’s disease have characteristic clinical and neuropathologic profiles, but also share overlapping clinical features. This study aimed to analyze the gait of people with progressive supranuclear palsy (
Egerton Thorlene +2 more
doaj +1 more source
Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. [PDF]
, 2019 BackgroundProgressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by neuronal loss in the extrapyramidal system with pathologic accumulation of tau in neurons and glia.
Dickson, Dennis W +8 more
core +1 more source
Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease
NeuroImage: Clinical, 2016 Background: Advanced brain MR techniques are useful tools for differentiating Progressive Supranuclear Palsy from Parkinson's disease, although time-consuming and unlikely to be used all together in routine clinical work.
Stefano Zanigni +14 more
doaj +1 more source
Clinical Parkinsonism & Related Disorders, 2020 Background and Purpose: The clinical diagnosis of progressive supranuclear palsy can be challenging, as the clinical presentation overlaps with that of Parkinson's disease and multiple system atrophy.
Jessica Cooperrider +2 more
doaj +1 more source
Clinical Case Reports, 2023 Key Clinical Message Progressive supranuclear palsy (PSP) has many clinical features overlapping with other Parkinson syndromes and differentiation on clinical ground is difficult.
Baraka Alphonce +4 more
doaj +1 more source
Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning [PDF]
, 2023 To better understand the pathological and phenotypic heterogeneity of progressive supranuclear palsy and the links between the two, we applied a novel unsupervised machine learning algorithm (Subtype and Stage Inference) to the largest MRI data set to ...
Alexander, Daniel C +15 more
core
Falls in Progressive Supranuclear Palsy [PDF]
Movement Disorders Clinical Practice, 2019 ABSTRACTBackgroundDespite falls being an almost universal clinical feature and central to the presentation and diagnostic criteria of progressive supranuclear palsy, our understanding of falls is surprisingly limited and there are few effective treatment options.ObjectivesTo provide an overview of the topic of the impact, assessment, mechanism, and ...
Brown, Fraser S +3 more
openaire +3 more sources